Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

NCT03018730 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

BIOLOGICAL: PRX-102 (pegunigalsidase alfa)

Sponsor

Protalix

Collaborators

[object Object]